Sofinnova Investments, Inc.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Sofinnova Investments, Inc. reported 56 stock positions worth $1.2 billion. Its top holding was Natera (NTRA) at 16.3% of the portfolio, followed by Vera Therapeutics (VERA, 10.2%) and Novo-Nordisk A/S-Spons ADR (NVO, 7.2%). Compared with Q2 2024, it opened 11 new positions, sold out of 26, added to 21 and reduced 15. The biggest buy was a new position in Bioage Labs (BIOA) and the biggest sale an exit from Ascendis Pharma A/S (ASND).
- Most Recent 13F
- Q2 2026
- Location
- Menlo Park, CA
- CIK
- 0001631134
- Portfolio Value
- $1.2B (Q3 2024)
- SEC Filing
- 0001104659-24-117589 ↗ filed Nov 13, 2024
Holdings Value
Holdings 56 stocks · $1.2B
| NTRA Natera Inc. | 16.30% | 1,550,280 | $196.8M | No change |
| VERA Vera Therapeutics Inc. | 10.23% | 2,793,987 | $123.5M | No change |
| NVO Novo-Nordisk A/S-Spons ADR | 7.16% | 726,329 | $86.5M | Add +11.8% |
| AZN Astrazeneca PLC-Spons ADR | 5.22% | 809,406 | $63.1M | Add +1.0% |
| IDYA Ideaya Biosciences Inc. | 4.59% | 1,749,455 | $55.4M | Add +51.9% |
| ELAN Elanco Animal Health Inc. | 4.28% | 3,518,684 | $51.7M | Add +22.9% |
| BIOA Bioage Labs Inc. | 3.97% | 2,304,901 | $47.9M | New |
| INCY Incyte Corp. | 3.91% | 714,176 | $47.2M | New |
| RAPP Rapport Therapeutics Inc. | 3.38% | 1,995,594 | $40.9M | Add +2.3% |
| AVBP Arrivent Biopharma Inc. | 3.30% | 1,696,752 | $39.9M | No change |
| AXSM Axsome Therapeutics Inc. | 2.82% | 379,527 | $34.1M | Add +22.4% |
| SLNO Soleno Therapeutics Inc. | 2.45% | 586,344 | $29.6M | Add +5.8% |
| YMAB Y-Mabs Therapeutics Inc. | 2.39% | 2,194,278 | $28.9M | No change |
| DYN Dyne Therapeutics Inc. | 2.30% | 772,070 | $27.7M | Reduce -52.5% |
| COGT Cogent Biosciences Inc. | 2.03% | 2,265,230 | $24.5M | Reduce -18.3% |
| SVRA Savara Inc. | 1.99% | 5,662,550 | $24.0M | Add +5.7% |
| INZY Inozyme Pharma Inc. | 1.85% | 4,280,308 | $22.4M | No change |
| JAZZ Jazz Pharmaceuticals PLC | 1.74% | 188,562 | $21.0M | New |
| INSM Insmed Inc. | 1.73% | 286,307 | $20.9M | Add +25.7% |
| SNDX Syndax Pharmaceuticals Inc. | 1.25% | 786,999 | $15.1M | Reduce -63.5% |
| RYTM Rhythm Pharmaceuticals Inc. | 1.20% | 276,678 | $14.5M | New |
| EW Edwards Lifesciences Corp. | 1.11% | 202,898 | $13.4M | Reduce -72.0% |
| BSX Boston Scientific Corp. | 0.94% | 135,819 | $11.4M | Reduce -20.6% |
| PHVS Pharvaris NV | 0.92% | 600,302 | $11.1M | Reduce -0.2% |
| EWTX Edgewise Therapeutics Inc. | 0.85% | 384,767 | $10.3M | Reduce -19.1% |
| IMNM Immunome Inc. | 0.82% | 676,766 | $9.9M | Add +3.2% |
| GH Guardant Health Inc. | 0.77% | 406,645 | $9.3M | New |
| RVMD Revolution Medicines Inc. | 0.76% | 203,271 | $9.2M | Reduce -55.3% |
| INBX Inhibrx Biosciences Inc. | 0.70% | 536,068 | $8.4M | Add +15.7% |
| TGTX TG Therapeutics Inc. | 0.69% | 358,644 | $8.4M | Reduce -80.7% |
| AEROVATE THERAPEUTICS INC | 0.65% | 3,758,686 | $7.9M | No change |
| ESTA Establishment Labs Holdings | 0.65% | 181,476 | $7.9M | Reduce -57.7% |
| MRNS Marinus Pharmaceuticals Inc. | 0.64% | 4,386,177 | $7.7M | Add +5.7% |
| JANX Janux Therapeutics Inc. | 0.62% | 164,770 | $7.5M | New |
| CABA Cabaletta Bio Inc. | 0.60% | 1,533,883 | $7.2M | Add +25.7% |
| ACHV Achieve Life Sciences Inc. | 0.59% | 1,514,032 | $7.2M | Add +9.1% |
| KURA Kura Oncology Inc. | 0.48% | 296,884 | $5.8M | Reduce -64.0% |
| PAHC Phibro Animal Health Corp. Class A | 0.44% | 238,184 | $5.4M | Add +0.5% |
| ILMN Illumina Inc. | 0.44% | 40,611 | $5.3M | New |
| ERAS Erasca Inc. | 0.42% | 1,842,668 | $5.0M | Add +8.4% |
| IMTX Immatics NV | 0.36% | 386,100 | $4.4M | Reduce -51.5% |
| NARI Inari Medical Inc. | 0.31% | 90,327 | $3.7M | Reduce -42.0% |
| BDX Becton Dickinson and Co. | 0.30% | 15,191 | $3.7M | New |
| NXTC Nextcure Inc. | 0.30% | 2,671,856 | $3.7M | No change |
| TMO Thermo Fisher Scientific Inc. | 0.30% | 5,770 | $3.6M | New |
| EXAS Exact Sciences Corp. | 0.21% | 37,637 | $2.6M | Reduce -79.3% |
| IRON Disc Medicine Inc. | 0.17% | 41,352 | $2.0M | Add +41.4% |
| BOLT Bolt Biotherapeutics Inc. | 0.15% | 2,754,437 | $1.8M | No change |
| GPCR Structure Therapeutics Inc. | 0.14% | 38,792 | $1.7M | Add +335.1% |
| CATX Perspective Therapeutics Inc. | 0.13% | 120,632 | $1.6M | Reduce -8.7% |
| RNAM Avidity Biosciences Inc. | 0.12% | 30,472 | $1.4M | Add +42.2% |
| VIR Vir Biotechnology Inc. | 0.08% | 129,246 | $968K | New |
| ATXS Astria Therapeutics Inc. | 0.08% | 85,640 | $943K | Add +41.1% |
| IKENA ONCOLOGY INC | 0.05% | 382,616 | $662K | No change |
| REPL Replimune Group Inc. | 0.04% | 48,138 | $528K | New |
| LUNG Pulmonx Corp. | 0.04% | 62,313 | $517K | Add +3.4% |
Options reported separately and not counted above: NVS puts ($23.0M), SLNO puts ($15.1M), AXSM puts ($13.5M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $852K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | 366,568 | $852K | Add +5.1% |
Total filed on the 13F, all lines: $1.2B.
Portfolio Sells Q2 2024 → Q3 2024
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −6.31 |
| SYK Stryker Corp. | Sold out | 0.00% | −4.14 |
| ALGN Align Technology Inc. | Sold out | 0.00% | −3.33 |
| EW Edwards Lifesciences Corp. | Reduce -72.0% | 1.11% | −3.11 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −2.45 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.27 |
| IDXX Idexx Laboratories Inc. | Sold out | 0.00% | −1.96 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.95 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -63.5% | 1.25% | −1.53 |
| TGTX TG Therapeutics Inc. | Reduce -80.7% | 0.69% | −1.39 |
| DYN Dyne Therapeutics Inc. | Reduce -52.5% | 2.30% | −1.32 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −1.28 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −1.25 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −0.78 |
| PODD Insulet Corp. | Sold out | 0.00% | −0.78 |
| AXONICS INC | Sold out | 0.00% | −0.64 |
| KURA Kura Oncology Inc. | Reduce -64.0% | 0.48% | −0.59 |
| ESTA Establishment Labs Holdings | Reduce -57.7% | 0.65% | −0.58 |
| PEPG Pepgen Inc. | Sold out | 0.00% | −0.56 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −0.44 |
| WAT Waters Corp. | Sold out | 0.00% | −0.40 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.36 |
| RVMD Revolution Medicines Inc. | Reduce -55.3% | 0.76% | −0.35 |
| EXAS Exact Sciences Corp. | Reduce -79.3% | 0.21% | −0.27 |
| BAX Baxter International Inc. | Sold out | 0.00% | −0.25 |
| IMTX Immatics NV | Reduce -51.5% | 0.36% | −0.22 |
| AVTR Avantor Inc. | Sold out | 0.00% | −0.19 |
| TFX Teleflex Inc. | Sold out | 0.00% | −0.18 |
| NARI Inari Medical Inc. | Reduce -42.0% | 0.31% | −0.16 |
| MASI Masimo Corp. | Sold out | 0.00% | −0.16 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.08 |
| ZBH Zimmer Biomet Holdings Inc. | Sold out | 0.00% | −0.07 |
| LIVN Livanova PLC | Sold out | 0.00% | −0.07 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.04 |
| PDSB PDS Biotechnology Corp. | Sold out | 0.00% | −0.03 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.02 |
| CATX Perspective Therapeutics Inc. | Reduce -8.7% | 0.13% | +0.05 |
| BSX Boston Scientific Corp. | Reduce -20.6% | 0.94% | +0.11 |
| PHVS Pharvaris NV | Reduce -0.2% | 0.92% | +0.21 |
| EWTX Edgewise Therapeutics Inc. | Reduce -19.1% | 0.85% | +0.31 |
| COGT Cogent Biosciences Inc. | Reduce -18.3% | 2.03% | +0.55 |
Portfolio Buys Q2 2024 → Q3 2024
| BIOA Bioage Labs Inc. | New | 3.97% | +3.97 |
| INCY Incyte Corp. | New | 3.91% | +3.91 |
| IDYA Ideaya Biosciences Inc. | Add +51.9% | 4.59% | +2.04 |
| JAZZ Jazz Pharmaceuticals PLC | New | 1.74% | +1.74 |
| ELAN Elanco Animal Health Inc. | Add +22.9% | 4.28% | +1.67 |
| NVO Novo-Nordisk A/S-Spons ADR | Add +11.8% | 7.16% | +1.32 |
| AZN Astrazeneca PLC-Spons ADR | Add +1.0% | 5.22% | +1.28 |
| AXSM Axsome Therapeutics Inc. | Add +22.4% | 2.82% | +1.25 |
| RYTM Rhythm Pharmaceuticals Inc. | New | 1.20% | +1.20 |
| SLNO Soleno Therapeutics Inc. | Add +5.8% | 2.45% | +1.03 |
| GH Guardant Health Inc. | New | 0.77% | +0.77 |
| INSM Insmed Inc. | Add +25.7% | 1.73% | +0.77 |
| SVRA Savara Inc. | Add +5.7% | 1.99% | +0.63 |
| JANX Janux Therapeutics Inc. | New | 0.62% | +0.62 |
| RAPP Rapport Therapeutics Inc. | Add +2.3% | 3.38% | +0.52 |
| ILMN Illumina Inc. | New | 0.44% | +0.44 |
| MRNS Marinus Pharmaceuticals Inc. | Add +5.7% | 0.64% | +0.33 |
| IMNM Immunome Inc. | Add +3.2% | 0.82% | +0.32 |
| BDX Becton Dickinson and Co. | New | 0.30% | +0.30 |
| TMO Thermo Fisher Scientific Inc. | New | 0.30% | +0.30 |
| INBX Inhibrx Biosciences Inc. | Add +15.7% | 0.70% | +0.28 |
| PAHC Phibro Animal Health Corp. Class A | Add +0.5% | 0.44% | +0.19 |
| ACHV Achieve Life Sciences Inc. | Add +9.1% | 0.59% | +0.18 |
| ERAS Erasca Inc. | Add +8.4% | 0.42% | +0.16 |
| GPCR Structure Therapeutics Inc. | Add +335.1% | 0.14% | +0.12 |
| IRON Disc Medicine Inc. | Add +41.4% | 0.17% | +0.09 |
| VIR Vir Biotechnology Inc. | New | 0.08% | +0.08 |
| RNAM Avidity Biosciences Inc. | Add +42.2% | 0.12% | +0.06 |
| REPL Replimune Group Inc. | New | 0.04% | +0.04 |
| ATXS Astria Therapeutics Inc. | Add +41.1% | 0.08% | +0.04 |
| CABA Cabaletta Bio Inc. | Add +25.7% | 0.60% | +0.02 |
| LUNG Pulmonx Corp. | Add +3.4% | 0.04% | +0.02 |
Options Activity Q2 2024 → Q3 2024
| QQQ Invesco QQQ Trust Series 1 | put | Sold out | 400,000 | $191.6Mbefore exit |
| EW Edwards Lifesciences Corp. | put | Sold out | 500,000 | $46.2Mbefore exit |
| ABT Abbott Laboratories | call | Sold out | 390,200 | $40.5Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 250,000 | $23.2Mbefore exit |
| NVS Novartis AG-Sponsored ADR | put | New | 200,000 | $23.0M |
| ISRG Intuitive Surgical Inc. | put | Sold out | 50,000 | $22.2Mbefore exit |
| SLNO Soleno Therapeutics Inc. | put | New | 300,000 | $15.1M |
| AXSM Axsome Therapeutics Inc. | put | New | 150,000 | $13.5M |
| ALNY Alnylam Pharmaceuticals Inc. | call | Sold out | 50,000 | $12.2Mbefore exit |
| SVRA Savara Inc. | put | Sold out | 150,000 | $605Kbefore exit |
| AMLX Amylyx Pharmaceuticals Inc. | put | Sold out | 300,000 | $570Kbefore exit |
| MRNS Marinus Pharmaceuticals Inc. | call | Sold out | 104,700 | $122Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2024 → Q3 2024
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | Add +5.1% | 366,568 | $852K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 53 | $1.9B | NTRA, VERA, GMAB, JAZZ, RAPP |
| Q1 2026 | 61 | $2.0B | NTRA, BMY, JAZZ, VERA, UTHR |
| Q4 2025 | 60 | $2.3B | NTRA, JAZZ, AZN, VERA, BMY |
| Q3 2025 | 55 | $1.6B | NTRA, GILD, VERA, UTHR, JAZZ |
| Q2 2025 | 55 | $1.5B | NTRA, GILD, LLY, JAZZ, VERA |
| Q1 2025 | 59 | $1.3B | NTRA, SYK, VERA, JAZZ, MDT |
| Q4 2024 | 60 | $1.4B | NTRA, VERA, GILD, ABBV, JAZZ |
| Q3 2024 | 56 | $1.2B | NTRA, VERA, NVO, AZN, IDYA |
| Q2 2024 | 71 | $1.6B | NTRA, VERA, ASND, NVO, EW |
| Q1 2024Amended | 66 | $1.7B | NTRA, VERA, ASND, AEROVATE THERAPEUTICS INC, MRK |